Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...